Abcellera BiologicsÂ Inc (ABCL) Peer Comparison

$11.75

$0.39 (3.39%)

As on 03-Sep-2026 11:36EDT

Market cap

$3,678 Mln

Revenue (TTM)

$66 Mln

P/E Ratio

--

P/B Ratio

4.5

Div. Yield

0 %

Edit

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Market cap ($ Mln)	3,678	5,809	2,167	345	430
Revenue ($ Mln)	66	--	312	0	59
Net Profit ($ Mln)	-164.66	-409.20	314.11	-37.54	-3.25
Net Margin (%)	-248.83	--	100.84	134,079.79	-5.49
RoE (%)	-17.68	-44.86	52.52	-79.49	-8.35
Price to Earnings	--	--	7.14	--	--
Price-To-Book	4.48	4.83	3.57	9.49	9.71

Cashflow
Ratios

Cashflow ($ Mln)

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Cash From Operating Activities	-131.30	-279.12	135.66	-29.06	-12.47
Cash Flow from Investing Activities	87.75	218.00	-32.77	-2.19	--
Cash from Financing Activities	14.08	117.11	-106.11	43.88	22.63
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
ROCE (%)	-13.12	-51.11	51.61	-67.28	-40.15
ROE (%)	-17.68	-44.86	52.52	-79.49	-8.35
ROA (%)	-11.64	-27.75	42.65	-60.11	-3.23
EBIT Margin (%)	-304.58	--	54.20	133,972.64	-4.19
Net Margin (%)	-248.83	-4,612.13	100.84	134,079.79	-5.49
Cash Profit Margin (%)	0.00	--	0.00	3.35	0.00

Growth Ratios

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Revenue Growth (%)	101.28	--	19.76	-100.20	77.83
EBIT Growth (%)	23.59	3.41	151.91	-26.93	70.81
Net Profit Growth (%)	0.61	-47.07	418.03	-26.91	72.99
EPS Growth (%)	2.53	-34.29	434.98	-6.40	73.38
Book Value Growth (%)	-13.08	55.33	96.66	12.47	531.86

Valuation Ratios

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Price / Earnings	-6.98	-10.27	7.70	-11.41	-24.64
Price / Book Value	1.06	6.11	3.81	6.66	6.85
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-4.24	-8.80	14.79	-9.61	-27.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.01	0.00	0.03	0.00	0.00
Current Ratio	12.77	21.02	5.42	6.72	5.85
Quick Ratio	12.63	21.02	4.97	6.72	5.66
Interest Coverage	-11.19	--	17.75	--	-2.43

Operating Efficiency Ratios

	Abcellera BiologicsÂ Inc (ABCL)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debtors to sales (%)	144.21	18.28	13.21	0.00	39.29
Asset Turnover	0.05	0.00	0.42	0.00	0.59
Receivable days	596.85	69.15	50.32	--	147.53
Inventory Days	40.15	--	474.76	--	127.22
Payable days	377.52	643.10	47.52	--	381.73
Cash Conversion Cycle	259.48	--	477.57	--	-106.97

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly